Developing Best-in-Class Radiopharmaceuticals for Cancer Patients
Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD. Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.